医学
化疗
胃食管交界处
围手术期
内科学
危险系数
外科
胃肠病学
肿瘤科
癌症
食管胃交界处
生存分析
总体生存率
临床试验
胃
作者
Run‐Cong Nie,Ying Jin,Cheng-Cai Liang,Yuan-Fang Li,Yingbo Chen,Xiaowei Sun,Wen‐Long Guan,Zi Wang,H J Qiu,Wei Wang,Shi Chen,Delong Zhang,Yihong Ling,S Y Xi,Mu-Yan Cai,Jun Chi,Q T Yang,Zhi-Min Liu,Yuanxiang Guan,Yong-Ming Chen
摘要
The NEOSUMMIT-01 trial previously showed that adding the PD-1 antibody toripalimab to perioperative chemotherapy improved the pathologic response in patients with locally advanced gastric or gastroesophageal junction cancer. Here, we present the event-free survival (EFS) and overall survival (OS) after extended follow-up. A total of 108 patients were enrolled (toripalimab plus chemotherapy, n = 54; chemotherapy alone, n = 54). At the data cutoff date (August 29, 2025), the median follow-up was 43.2 months (interquartile range: 36.6-53.7). The 3-year EFS was 74.7% (95% CI, 63.6% to 87.7%) in the toripalimab plus chemotherapy group and 56.2% (95% CI, 43.3% to 73.0%) in the chemotherapy group, with a hazard ratio (HR) of 0.51 (95% CI, 0.27 to 0.98; P = .044). The 3-year OS was 81.3% (95% CI, 71.4% to 92.4%) versus 72.2% (95% CI, 61.2% to 85.2%), respectively, with an HR of 0.45 (95% CI, 0.21 to 0.95; P = .036). The survival benefits were consistent across most predefined subgroups and were maintained in the analysis excluding patients with dMMR. In conclusion, perioperative toripalimab plus chemotherapy significantly improved 3-year EFS and OS compared with chemotherapy alone, suggesting it as a promising treatment option for patients with locally advanced gastric or gastroesophageal junction cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI